Disease · MONDO_0000082

pelvic organ prolapse

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pelvic organ prolapse. Diseases, record MONDO_0000082. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000082

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pelvic organ prolapse; Open Targets
Open Targets ID: MONDO_0000082; Open Targets
Other names: Organ Prolapse, Pelvic, Organ Prolapses, Pelvic, POP, Pelvic Organ Prolapses, Prolapse, Pelvic Organ, Prolapse, Urogenital, Prolapse, Vaginal Vault, Prolapses, Pelvic Organ, Prolapses, Urogenital, Prolapses, Vaginal Vault, Urogenital Prolapse, Urogenital Prolapses, Vaginal Vault Prolapse, Vaginal Vault Prolapses, Vault Prolapse, Vaginal, Vault Prolapses, Vaginal; Open Targets
MeSH: D056887; MeSH
Highest stage of its drugs: Phase 3, for 4 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESTROGEN	CHEMBL592868	Small molecule	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
ALFACALCIDOL	CHEMBL1601669	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ESTRIOL	CHEMBL193482	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOLTERODINE	CHEMBL1382	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
ESTROGENS, CONJUGATED	CHEMBL1201649		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	3	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
ESR2	Estrogen receptor	2	Estrogen receptor agonist; Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2100	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	1	Muscarinic acetylcholine receptor M2 antagonist	Phase 3	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 antagonist	Phase 3	https://conductscience.org/library/genes/1131	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor agonist	Unknown	https://conductscience.org/library/genes/2740	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SCN4A	Sodium channel protein type 4 subunit alpha	1	Sodium channel protein type IV alpha subunit blocker	Phase 1/2	https://conductscience.org/library/genes/6329	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03040011	Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery	Phase 1/2	79	2020-03-09	Pelvic Organ Prolapse, Surgery, Postoperative Pain	BUPIVACAINE, DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT03338400	Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?	Phase 2	51	2019-05-10	Quality of Recovery, Same Day Surgery, Nausea and Vomiting, Postoperative, Vaginal Prolapse	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01648751	Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse	Not applicable	21	2024-09-19	Pelvic Organ Prolapse	ESTROGEN	Its record names the disease	ClinicalTrials.gov
NCT02599311	the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery	Phase 3	1,000		Pelvic Organ Prolapse	TOLTERODINE	Its record names the disease	ClinicalTrials.gov
NCT07175805	Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy		200		Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT07030426	Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery	Phase 3	180		Pelvic Organ Prolapse (POP)	ESTROGEN	Its record names the disease	ClinicalTrials.gov
NCT01843166	Vaginal Estrogen With Pessary Treatment	Not applicable	150		Vaginal Infection, Urinary Tract Infection, Quality of Life	ESTROGENS, CONJUGATED	Its record names the disease	ClinicalTrials.gov
NCT04733560	Preoperative Analgesia by Infiltration of the Pudendal Nerve Prior to Sacrospinous Ligament Suspension	Not applicable	50		Pelvic Organ Prolapse	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT05505253	Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients	Phase 3	48		Pelvic Organ Prolapse	ALFACALCIDOL	Its record names the disease	ClinicalTrials.gov
NCT06391372	Effect of Local Estriol Treatment Before Vaginal Repair Surgery	Phase 3	36		Pelvic Organ Prolapse, Pelvic Floor Disorders, Menopause, Vaginal Atrophy	ESTRIOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dexamethasone vs Normal Saline: deaths from any cause	0 of 24	0 of 24	48	NCT03338400	Trial comparisons
Dexamethasone vs Normal Saline: serious adverse events	0 of 24	0 of 24	48	NCT03338400	Trial comparisons
Normal Saline vs Dexamethasone: Nausea, Vomiting	2 of 24	2 of 22	46	NCT03338400	Trial comparisons
Normal Saline vs Dexamethasone: Readmissions	4 of 24	1 of 22	46	NCT03338400	Trial comparisons
Normal Saline vs Dexamethasone: Urinary Tract Infections	1 of 24	2 of 22	46	NCT03338400	Trial comparisons
Vaginal Estrogen vs Placebo Cream: deaths from any cause	0 of 9	0 of 11	20	NCT01648751	Trial comparisons
Vaginal Estrogen vs Placebo Cream: serious adverse events	0 of 9	0 of 11	20	NCT01648751	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33935807	RESULT	1	PubMed
31039170	RESULT	1	PubMed
42975544	DERIVED	1	PubMed
33278291	DERIVED	1	PubMed
33207004	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000082

GET https://conductscience.org/api/diseases/v1/MONDO_0000082/drugs

API reference For AI assistants